Paul Hastings announced that it represented UBS Securities, Wells Fargo Securities and General Electric Capital as lead arrangers in connection with the amendment of the existing amended and restated first lien credit agreement and the second lien credit agreement for Pharmaceutical Research Associates. The firm also represented UBS AG, Stamford Branch, as administrative agent.

The amendment will, among other things, permit the incurrence of first lien incremental term loans and second lien incremental term loans for the purposes of, among other things, the payment of a shareholder dividend and the acquisition of ClinStar, a clinical research organization.

Leveraged finance partners Mario Ippolito and Michael Michetti led the Paul Hastings team, which also included associates Christopher Ross, Joseph Fastiggi, Heidi Spalholz and Valerie Silverman.